['multiple myeloma']
['bortezomib-melphalan', 'melphalan']

        Inclusion Criteria:

          -  Must have results from their initial diagnosis available at the time of screening to
             confirm all the following :

               1. Diagnosis of multiple myeloma according to the diagnostic

               2. Symptomatic de novo Multiple Myeloma

          -  Be eligible for high-dose therapy with autologous stem cell transplantation

          -  Autologous cell graft with a total number of CD 34 cells > or = 5 X 106/kg before
             freezing

        Exclusion Criteria:

          -  Progressive disease

          -  Females participants pregnant or breast-feeding

          -  A known infection by the human immunodeficiency virus

          -  An active viral hepatitis B or C

          -  Unstable angina or myocardial infarction within 4 months prior to inclusion, heart
             failure NYHA class III or IV angina, uncontrolled, history of severe coronary artery
             disease, an uncontrolled serious ventricular arrhythmia, a sick sinus syndrome, or
             electrocardiographic evidence of acute ischemia or conduction disturbances grade 3
             unless the patient has a pacemaker

          -  Uncontrolled hypertension or uncontrolled diabetes within 14 days before enrollment

          -  A history of another malignancy. If cancer was diagnosed more than 10 years and
             considered as cured, an authorization may be requested on a case-by-case basis after
             discussion with the principal investigator

          -  A significant neuropathy of grade 3-4 or grade 2 with pain in the 14 days prior to
             enrollment
      